UK medical cannabis registry: assessment of clinical outcomes in patients with headache disorders

References

• Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the global burden of disease study 2010. Lancet. 2012;380(9859):2129–2143.
   PubMed Web of Science ®Google Scholar
• Ahmed F. Headache disorders: differentiating and managing the common subtypes. Br J Pain. 2012;6(3):124–132.
   PubMedGoogle Scholar
• Steiner TJ, Stovner LJ, Jensen R, et al. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137.
   PubMed Web of Science ®Google Scholar
• Fuller G, Kaye C. Headaches. BMJ. 2007;334(7587):254–256.
   PubMedGoogle Scholar
• Buse DC, Loder EW, Gorman JA, et al. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;53(8):1278–1299.
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808.
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Headache Pain. 2013;14:1.
   PubMed Web of Science ®Google Scholar
• World health report. WHO, Geneva. World Health Organisation. 2001
   Google Scholar
• Latinovic R. Headache and migraine in primary care: consultation, prescription, and referral rates in a large population. J Neurol Neurosurg Psychiatry. 2005;77:385–387.
   Web of Science ®Google Scholar
• Goldstein J, Camargo C, Pelletier A, et al. Headache in United States Emergency Departments. Cephalalgia. 2006;26:684–690.
   PubMed Web of Science ®Google Scholar
• Negro A, RD S. Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre. J Headache Pain. 2019;20:120.
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Burstein R, et al. * Migraine. Nat Rev Dis Primers. 2022;8:1.
   PubMed Web of Science ®Google Scholar
• National Institute of Health and Care Excellence (NICE, 2021). Guidelines/guidance Migraine. 2021
   Google Scholar
• Evers S, Áfra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol. 2009;16:968–981.
   PubMed Web of Science ®Google Scholar
• Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35:478–488.
   PubMed Web of Science ®Google Scholar
• Vikelis M, Spingos KC, Rapoport AM. A new era in headache treatment. Neurol Sci. 2018;39:47–58.
   PubMed Web of Science ®Google Scholar
• Diener H-C, Dodick D, Evers S, et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol. 2019;18:891–902.
   PubMed Web of Science ®Google Scholar
• Greco R, Demartini C, Zanaboni AM, et al. The endocannabinoid system and related lipids as potential targets for the treatment of migraine‐related pain. Headache. 2022;62:227–240.
   PubMedGoogle Scholar
• Greco R, Demartini C, Zanaboni AM, et al. * Endocannabinoid system and migraine pain: an update. Front Neurosci. 2018;12:172.
   PubMed Web of Science ®Google Scholar
• Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol. 2020;16:9–29.
   PubMed Web of Science ®Google Scholar
• Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ-tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199–215.
   PubMed Web of Science ®Google Scholar
• Finn D, Haroutounian S, Hohmann AG;, et al. Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. Pain. 2021;162:s5–25.
   PubMedGoogle Scholar
• Russo E. Clinical Endocannabinoid Deficiency (CECD): can this concept explain therapeutic benefits of cannabis. Neuro Endocrinol Lett. 2004;25:39.
   Web of Science ®Google Scholar
• Christiansen IM, Edvinsson JCA, Reducha PV, et al. Dual action of the cannabinoid receptor 1 ligand arachidonyl-2′-chloroethylamide on calcitonin gene-related peptide release. J Headache Pain. 2022;23:30.
   PubMed Web of Science ®Google Scholar
• Cupini L, Bari M, Battista N, et al. Biochemical Changes in Endocannabinoid System are Expressed in Platelets of Female but not Male Migraineurs. Cephalalgia. 2006;26:277–281.
   PubMed Web of Science ®Google Scholar
• Hanuš LO, Meyer SM, Muñoz E, et al. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016;33:1357–1392.
   PubMed Web of Science ®Google Scholar
• Wang L, Hong PJ, May C, et al. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ. 2021;374(8305):n1034.
   PubMedGoogle Scholar
• Lintzeris N, Mills L, Suraev A, et al. Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). Harm Reduct J. 2020;17:37.
   PubMed Web of Science ®Google Scholar
• Rhyne DN, Anderson SL, Gedde M, et al. Effects of medical marijuana on migraine headache frequency in an adult population. Pharmacother J Human Pharmacol Drug Ther. 2016;36:505–510.
   Google Scholar
• Cuttler C, Spradlin A, Cleveland MJ, et al. Short- and long-term effects of cannabis on headache and migraine. J Pain. 2020;21:722–730.
   PubMed Web of Science ®Google Scholar
• Pini LA, Guerzoni S, Cainazzo MM, et al. Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial. J Headache Pain. 2012;13:677–684.
   PubMed Web of Science ®Google Scholar
• Kilinc E, Ankarali S, Torun IE, et al. Receptor mechanisms mediating the anti‐neuroinflammatory effects of endocannabinoid system modulation in a rat model of migraine. Eur J Neurosci. 2022;55:1015–1031.
   PubMed Web of Science ®Google Scholar
• Akerman S, Holland PR, Lasalandra MP, et al. Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and “Triptan” receptors: implications in migraine. J Neurosci. 2013;33:14869–14877.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Mulpuri Y, Izraylev M, et al. Selective targeting of peripheral cannabinoid receptors prevents behavioral symptoms and sensitization of trigeminal neurons in mouse models of migraine and medication overuse headache. Pain. 2021;162:2246–2262.
   PubMed Web of Science ®Google Scholar
• Kandasamy R, Dawson CT, Craft RM, et al. Anti-migraine effect of ∆9-tetrahydrocannabinol in the female rat. Eur J Pharmacol. 2018;818:271–277.
   PubMed Web of Science ®Google Scholar
• Akerman S, Kaube H, Goadsby PJ. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther. 2004;309:56–63.
   PubMed Web of Science ®Google Scholar
• Ergisi M, Erridge S, Harris M, et al. An updated analysis of clinical outcome measures across patients from the UK medical cannabis registry. Cannabis Cannabinoid Res. 2022. Epub. Doi:10.1089/can.2021.0145.
   Google Scholar
• Orsolini L, Chiappini S, Volpe U, et al. Use of medicinal cannabis and synthetic cannabinoids in Post-Traumatic Stress Disorder (PTSD): a systematic review. Medicina (B Aires). 2019;55:525.
   Google Scholar
• Martinotti G, Di Iorio G, Sepede G, et al. Cannabis use and psychosis: theme introduction. Curr Pharm Des. 2012;18:4991–4998.
   PubMed Web of Science ®Google Scholar
• Ricci V, Martinotti G, Ceci F, et al. Duration of untreated disorder and cannabis use: an observational study on a cohort of young Italian patients experiencing psychotic experiences and dissociative symptoms. Int J Environ Res Public Health. 2021;18:12632.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Iorio G, Tedeschi D, et al. Prevalence and intensity of basic symptoms among cannabis users: an observational study. Am J Drug Alcohol Abuse. 2011;37:111–116.
   PubMed Web of Science ®Google Scholar
• Baraldi C, Lo Castro F, Negro A, et al. Oral cannabinoid preparations for the treatment of chronic migraine: a retrospective study. Pain Med. 2022;23:396–402.
   PubMed Web of Science ®Google Scholar
• Ojelabi AO, Graham Y, Haighton C, et al. A systematic review of the application of Wilson and Cleary health-related quality of life model in chronic diseases. Health Qual Life Outcomes. 2017;15:241.
   PubMed Web of Science ®Google Scholar
• The CP. NICE guideline on medicinal cannabis: keeping pandora’s box shut tight? Med Law Rev. 2020;28:401–411.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–1457.
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare products Regulatory Agency. The supply of unlicensed cannabis-based products for medicinal use in humans. 2020
   Google Scholar
• Brusselaers N, Lagergren J. The Charlson comorbidity index in registry-based research. Methods Inf Med. 2017;56:401–406.
   PubMed Web of Science ®Google Scholar
• Erridge S, Salazar O, Kawka M, et al. An initial analysis of the UK medical cannabis registry: outcomes analysis of first 129 patients. Neuropsychopharmacol Rep. 2021;41:362–370.
   PubMed Web of Science ®Google Scholar
• Lee D, de Keizer N, Lau F, et al. Literature review of SNOMED CT use. J Am Med Inf Assoc. 2014;21:e11–9.
   PubMed Web of Science ®Google Scholar
• National Institute of Health and Care Excellence (NICE, 2022). Medicines guidance: prescribing in palliative care. British National Formulary. 2022. [cited 2022 Aug 01]. Available from: https://bnf.nice.org.uk/medicines-guidance/prescribing-in-palliative-care/
   Google Scholar
• Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item short-form survey for measuring headache impact: the HIT-6TM. Qual Life Res. 2003;12:963–974.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Lipton RB, Dowson AJ, et al. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56:S20–8.
   PubMed Web of Science ®Google Scholar
• Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–1736.
   PubMed Web of Science ®Google Scholar
• Spitzer RL, Kroenke K, Williams JBW, et al. A brief measure for assessing generalized anxiety disorder. Arch Intern Med. 2006;166:1092.
   PubMed Web of Science ®Google Scholar
• Snyder E, Cai B, DeMuro C, et al. A new single-item sleep quality scale: results of psychometric evaluation in patients with chronic primary insomnia and depression. J Clin Sleep Med. 2018;14:1849–1857.
   PubMed Web of Science ®Google Scholar
• Ferguson L, Scheman J. Patient global impression of change scores within the context of a chronic pain rehabilitation program. J Pain. 2009;10:S73.
   Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2009
   Google Scholar
• Luedtke K, Basener A, Bedei S, et al. Outcome measures for assessing the effectiveness of non-pharmacological interventions in frequent episodic or chronic migraine: a Delphi study. BMJ Open. 2020;10:e029855.
   PubMed Web of Science ®Google Scholar
• Coeytaux RR, Kaufman JS, Chao R, et al. Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test. J Clin Epidemiol. 2006;59:374–380.
   PubMed Web of Science ®Google Scholar
• Carvalho GF, Luedtke K, Braun T. Minimal important change and responsiveness of the Migraine Disability Assessment Score (MIDAS) questionnaire. J Headache Pain. 2021;22:126.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Lombard L, Ruff DD, et al. Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study. J Headache Pain. 2020;21:20.
   PubMed Web of Science ®Google Scholar
• Lombard L, Farrar M, Ye W, et al. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J Headache Pain. 2020;21:41.
   PubMed Web of Science ®Google Scholar
• Sexton M, Cuttler C, Finnell JS, et al. A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy. Cannabis Cannabinoid Res. 2016;1:131–138.
   PubMedGoogle Scholar
• Azcarate PM, Zhang AJ, Keyhani S, et al. Medical reasons for marijuana use, forms of use, and patient perception of physician attitudes among the US population. J Gen Intern Med. 2020;35:1979–1986.
   PubMed Web of Science ®Google Scholar
• Census 2020. Drug misuse in England and Wales: year ending March 2020. United Kingdom; 2020
   Google Scholar
• Cahill SP, Lunn SE, Diaz P, et al. Evaluation of patient reported safety and efficacy of cannabis from a survey of medical cannabis patients in Canada. Front Public Health. 2021;9:626853.
   PubMed Web of Science ®Google Scholar
• Babson KA, Sottile J, Morabito D. Cannabis, cannabinoids, and sleep: a review of the literature. Curr Psychiatry Rep. 2017;19:23.
   PubMed Web of Science ®Google Scholar
• Bauer-Staeb C, Kounali D-Z, Welton NJ, et al. Effective dose 50 method as the minimal clinically important difference: evidence from depression trials. J Clin Epidemiol. 2021;137:200–208.
   PubMed Web of Science ®Google Scholar
• Lev-Ran S, Roerecke M, le Foll B, et al. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med. 2014;44:797–810.
   PubMed Web of Science ®Google Scholar
• Walsh JH, Maddison KJ, Rankin T, et al. Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo. Sleep. 2021;44:11.
   PubMed Web of Science ®Google Scholar
• Zhang N, Woldeamanuel Y. Medication Overuse Headache in chronic migraine patients using cannabis: a case-referent study. 2021;61(8):1234–1244.
   Google Scholar
• Wang T, Collet J-P, Shapiro S, et al. Adverse effects of medical cannabinoids: a systematic review. Can Med Assoc J. 2008;178:1669–1678.
   PubMed Web of Science ®Google Scholar
• Kandasamy R, Dawson CT, Hilgendorf TN, et al. Medication overuse headache following repeated morphine, but not ∆9-tetrahydrocannabinol administration in the female rat. Behav Pharmacol. 2018;29:469–472.
   PubMed Web of Science ®Google Scholar
• Couch D. Left behind: the scale of illegal cannabis use for medicinal intent in the UK. 2020
   Google Scholar
• Smuck M, Odonkor CA, Wilt JK, et al. The emerging clinical role of wearables: factors for successful implementation in healthcare. NPJ Digit Med. 2021;4:45.
   PubMed Web of Science ®Google Scholar
• Worth T. Cannabis’s chemical synergies. Nature. 2019;572:S12–3.
   PubMedGoogle Scholar